Veradermics (MANE) Net Income towards Common Stockholders (2025 - 2026)
Veradermics posted quarterly Net Income towards Common Stockholders of -$30.0 million for Q1 2026, down 105.81% year-on-year from $516.7 million in Q1 2025, and down 105.81% on a QoQ basis from -$14.6 million in Q1 2025.
Veradermics (MANE) has 2 years of Net Income towards Common Stockholders data on file, last reported at -$30.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 105.81% year-over-year to -$30.0 million; the trailing twelve-month figure through Mar 2026 stood at -$44.6 million (changed N/A YoY), and the FY2025 full-year result was -$83.4 million, down 205.36% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$30.0 million, down from -$14.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$14.6 million in Q1 2025 and bottomed at -$30.0 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Veradermics | 2.29 Bn | 2.29 Bn | - | -30.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.01 Mn |
| Mar 31, 2025 | -14.58 Mn |